Cell fusions in the developing mammal {#Sec1}
=====================================

The fusion between the sperm and the egg marks the beginning of a new individual and ensuing development of either man or beast depends upon a number of additional cell fusion events (reviewed by Ogle et al. [@CR69]). Thus, mononuclear cytotrophoblasts fuse to form the syncytiotrophoblast layer of the placenta in man and certain other mammals. Syncytiotrophoblasts control the exchange of gases, nutrients and waste products between the fetus and the mother, protect the fetus against the maternal immune system and are also responsible for the production of hormones, which like chorionic gonadotropin, regulate the continuation of pregnancy. In addition, in the developing individual, myoblasts fuse to form multinucleated skeletal muscle fibers, while cells of monocytic origin fuse to form osteoclasts, which participate in bone sculpturing and remodeling as well as in the regulation of serum calcium concentrations.

Cell fusions contribute to tissue repair {#Sec2}
========================================

It is well-known that skeletal muscle is regenerated through fusion of muscle fibers with satellite cells (Bischoff [@CR8]) and that macrophages may fuse to form multinucleated giant cells with enhanced phagocytic capabilities in response to injury and antigenic challenges (Vignery [@CR86]). Recent data indicate that additional cell fusions may contribute to tissue repair in the adult (Vassilopoulos et al. [@CR85]; Wang et al. [@CR89]). Bone-marrow-derived (BMD) cells have been shown to fuse with hepatic cells, nerve cells and gastrointestinal cells and the theory has been put forward that such fusions may serve to repair damaged or corrupted cells (Alvarez-Dolado et al. [@CR3]; Rizvi et al. [@CR75]; Vassilopoulos et al.[@CR85]; Wang et al. [@CR89]). However, it is still debated whether such fusions are important to tissue repair and whether they engage BMD stem cells or more differentiated fusogenic cells like monocytes/macrophages (reviewed by Vignery [@CR86]). Intriguingly, the accumulation of macrophages in injured organs may reflect not only the need to remove debris but also to repair compromised cells through heterotypic fusions (Vignery [@CR86]). Moreover, in recent transplant experiments, irradiated mice showed evidence of fusions between crypt stem cells and donor BMD cells (Rizvi et al. [@CR75]). In thus transplanted mice, representatives of all cell lineages derived from intestinal crypt stem cells (absorptive columnar, enteroendocrine, goblet and Paneth cells) showed expression of chromosomal markers characterizing donor BMD cells. This phenomenon appeared to depend upon tissue injury since expression of donor cell markers never was detected in non-irradiated mice (Rizvi et al. [@CR75]). An alternative to fusions has been suggested by Holmgren et al. ([@CR47]) and de la Taille et al. ([@CR25]), who have demonstrated that cells phagocytosing apoptotic cells may acquire functional DNA. Moreover, a mechanism of cell--cell invasion (entosis) was recently described and could potentially transfer DNA between cells (Overholtzer et al. [@CR71]). Thus, viral as well as normal sequences from apoptotic cells have been found to be active also in phagocytosing cells (Holmgren et al. [@CR47]). This observation challenges our understanding of apoptosis as an efficient way of clearing corrupted or alien DNA.

Cell fusions during viral infections {#Sec3}
====================================

Infections with enveloped viruses such as HIV-1 may also lead to cell fusions. The viral genome encodes envelope (Env) proteins, which bind to cell surface receptors and assist the virus in entering the cell. The infected cell commences to synthesize Env proteins, which, upon insertion in the plasmalemma, engages receptor proteins in neighboring cells and initiate fusions. Interestingly, modifications of the cytoplasmic tail of several Env proteins appear to modify fusions. Thus, proteolytic cleavage of the cytoplasmic tail regulates fusions and also cellular signaling events, such as tyrosine kinase activity, may be involved in regulation of virally induced cell fusions (Kubo et al. [@CR55]).

Receptor proteins may bind Env proteins from different classes of viruses. Thus, a cell infected by a specific virus becomes resistant to infections with other viruses that bind to the same receptor. This phenomenon, which probably reflects receptor saturation, has led to the grouping of retroviruses into different subtypes, which bind to the same receptor. Other types of viruses encode fusogenic proteins (like influenza hemagglutinin), which do not bind to surface receptors, but which liberate a fusion peptide in the acidic milieu of endosomes and thus initiate viral--host cell fusion following endocytic uptake of viral particles. Both these proteins and the Env proteins are referred to as class I viral fusion proteins and contain hydrophobic fusion peptides buried within their sequences. Following receptor engagement or endosomal acidification the fusion peptides are liberated by proteolytic cleavage. The cleaved peptides undergo conformational changes, resulting in hairpin-like, alpha-helical bundles, which bring the viral and cell membranes into close apposition and thereby facilitates fusion (reviewed by Chen and Olson [@CR21]).

Cancer--host cell fusions {#Sec4}
=========================

In [@CR2] Aichel suggested that cancer cells might spontaneously fuse with host cells to produce hybrids with supernumerary chromosomes that could evolve into cells of increased malignancy. Subsequent studies have confirmed this prediction by demonstrating that cells with mixed phenotypes spontaneously appear in co-cultures of normal and malignant cells (Barski and Cornefert [@CR7]; Busund et al. [@CR13]; Mortensen et al. [@CR68]; Wakeling et al. [@CR87]) (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). Additionally, transplanted tumor cells of animal (Busund et al. [@CR14]; Chakraborty et al. [@CR18]; Fortuna et al. [@CR31]; Kerbel et al. [@CR52]; Larizza et al. [@CR56]; Wiener et al. [@CR88], [@CR90]) or human (Goldenberg et al. [@CR37]; Goldenberg and Pavia [@CR36]; Mortensen et al. [@CR68]) origin may fuse with and acquire phenotypic characteristics of normal host cells (Fig. [4](#Fig4){ref-type="fig"}). In some of the in vivo studies, data suggested that the putative fusion partner was of macrophage or endothelial origin but, in most cases, definite identification was not achieved. In a few cases, it has also been demonstrated that the fused cells expressed genetic markers of both parental cell types (Goldenberg et al. [@CR37]; Mortensen et al. [@CR68]; Wiener et al. [@CR88], [@CR90]) (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). Mortensen et al. ([@CR68]) demonstrated that, initially after fusion, bi- or multinucleated cells formed and that such cells had the parental genomes seggregated in diffferent nuclei (heterokaryons) (Fig. [2](#Fig2){ref-type="fig"}a--e). Subsequently, mitotic figures appeared showing an admixture of the parental chromosomes (Fig. [2](#Fig2){ref-type="fig"}f--j). Eventually, cells with the parental genomes mixed in a single nucleus (synkaryons) were detected (Fig. [2](#Fig2){ref-type="fig"}k--o). In agreement with the notion that synkaryons appear after mitotic divison of heterokaryons, synkaryons are usually detected in pairs (Fig. [3](#Fig3){ref-type="fig"}). A few recent studies present compelling evidence that cells with genetic characteristics of hybrid cells also may appear in human tumors (Andersen et al. [@CR4]; Chakraborty et al. [@CR16]; Yilmaz et al. [@CR94]; Streubel et al. [@CR80]). Thus, in two cases of renal carcinomas, arising in bone marrow transplant recipients, some tumor cells showed genetic markers characterizing the healthy donor (Chakraborty et al. [@CR16]; Yilmaz et al. [@CR94]). Moreover, in patients with multiple myelomas, osteoclasts have been shown to contain an admixture of nuclei, of which some possess tumor-specific chromosomal translocations while others are devoid of translocations (Andersen et al. [@CR4]). Finally, lymphoma-specific genetic abnormalities were described in endothelial cells in B cell lymphomas (Streubel et al. [@CR80]). Although these data do not formally prove that tumor--host cell hybrids did form in these patients, the combined results from studies in vitro and in vivo do present compelling evidence that cell fusions do occur in tumors (reviewed by Pawelek [@CR73]). Fig. 1Cancer--endothelial cell fusion. Co-culture of human breast cancer (MCF-7) cells and human umbilical vein endothelial cells (*HUVEC*). Cells were stained for the cancer cell marker cytokeratin (*red*, **c**), the endothelial cell marker vimentin (*green*, **b**) and DNA (bisbenzimide, *blue*, **d**). Note in the merged image (**a**) one fused, multinucleated cell reacting for both cytokeratin and vimentin (*orange-yellow*)Fig. 2Chromosomal markers and cell fusions. Co-cultures of human breast cancer cells and bovine endothelial cells. The cultures were subjected to fluorescent in situ hybridization (*FISH*) with probes recognizing all bovine chromosomes (*green*; **b**, **g**, **l**) and all human chromosomes (*red*; **c**, **h**, **m**) and counter-stained for DNA with DAPI (*blue*; **d**, **i**, **n**) and observed in differential interference contrast (*DIC*; **e**, **j**, **o**). Merged *red-green* images are shown in **a**, **f**, **k**. Note that initially, binuclear cells (heterokaryons) form, having one bovine and one human nucleus (**a**--**e**). Occasionally, tri- or multinuclear cells with different admixtures of bovine and human nuclei are also detected. At longer times after mixing, mitotic figures, containing an admixture of bovine and human chromosomes appear (**f**--**j**) and, eventually, cells with a single nucleus, containing an admixture of the two genomes in mixture (synkaryons) are detected (**k**--**o**)Fig. 3Chromosomal markers and cell fusions. Mixed culture of human breast cancer cells and bovine endothelial cells submitted to double FISH as in Fig. [2](#Fig2){ref-type="fig"} (**a** double FISH; **b** combined DAPI and DIC). Low power micrograph showing a pair of synkaryons with the bovine and human genomes admixed in single nuclei (*arrows*). In addition, nuclei hybridizing only for the bovine (*green*) or only for the human (*red*) genome occurFig. 4Cancer--host cell fusion in vivo. **a**, **b**Section from lung of a nude mice injected with human breast cancer (MDA-MB-231) cells in the tail vein (Mortensen et al. [@CR68]). The section underwent FISH for the mouse genome (*red*) and the human genome (*green*) (**a**) and DNA was counterstained with DAPI (**b**; *blue*). Note one nucleus in which the human and mouse genome co-localize (*arrow*). C: Similar section, stained with an antibody detecting human (but not mouse) p53 (*red*; p53 is mutated and overexpressed by the breast cancer cells), an antibody to beta-catenin (to mark cell membranes) and for DNA with bisbenzimide (*blue*). Note a micrometastasis of human breast cancer cells having violet (*red* + *blue*) fluorescent nuclei. **d** Section stained for human p53 (*red*) and the endothelial marker von Willebrand factor (*green*) and DNA (*blue*). Note a human cancer cell with a violet (*red* + *blue*) nucleus showing membrane-staining for von Willebrand factor. Since von Willebrand factor is not normally expressed by the breast cancer cells, this image is suggestive of a fusion between a human breast cancer cell and a mouse endothelial cell. Similar results were obtained using double FISH for the human and mouse genome and imunofluorescent staining for von Willebrand factor (described by Mortensen et al. [@CR68])

The essential question regarding cancer--host cell fusions is, of course, if they are relevant to the patient. In fact, there are two opposing views. The first is based on early experiments on fusions induced to occur between cancer cells and normal cells in culture. With few exceptions, such experiments revealed that malignancy was suppressed (Harris et al. [@CR40]; Harris [@CR41]; Stanbridge [@CR79]; Wiener et al. [@CR88], [@CR90]). These studies were, in fact, seminal to the discovery of tumor suppressor genes (reviewed by Anderson and Stanbridge [@CR5]). Since tumor suppressor genes, like p53 and Rb, frequently are inactivated in cancer cells, fusions would present cancer cells with unperturbed tumor suppressors from the normal fusion partner and consequently initiate cell cycle arrest or apoptosis. Although, this certainly applied for the cell types studied in the contributions cited above, it may not be a general rule. Thus, production of monoclonal antibodies depends upon the fact that it is possible to fuse antibody-producing spleen cells with myeloma cells to obtain hybridomas that retain the unlimited proliferative ability of the tumor cell partner and the antibody production of the normal cell (Kohler and Milstein [@CR54]). In fact, several studies documented that some fusions may lead to cells of increased malignancy (Barski and Cornefert [@CR7]; Busund et al. [@CR14]; Chakraborty et al. [@CR17]; De Baetselier et al. [@CR24]; Kerbel et al. [@CR52]; Larizza et al. [@CR57]; Pawelek [@CR72]; Rachkovsky et al. [@CR74]). Possibly, the genetic make-up of tumors may dictate the outcome of individual cancer--host cell fusions. Moreover, fusions lead to aneuploidy and chromosomal instability, which characterizes most cancers and may, by itself, stimulate carcinogenesis (Duelli et al. [@CR28]).

Mechanisms behind cell--cell fusions {#Sec5}
====================================

Fusions between normal cells {#Sec6}
----------------------------

Cell fusion events must be extremely well controlled. Due to their major importance to fertilization, placentation, muscle development, bone structure, calcium homeostasis and the immune defense system, much effort has gone into elucidating mechanisms underlying cell--cell fusions. Additionally, the potential role of cell fusions as a repair mechanism and the role of cell fusions in cancer development and progression have further stimulated research in this field. In spite of this, much less is known about cell--cell fusion mechanisms than is known about how intracellular membranes fuse through v- and t-SNAREs. Interestingly, engineered flipping of the v- and t-SNARE machinery has been shown to promote cell--cell fusions (Weber et al. [@CR91]). However, it is evident that this mechanism is not a physiological mediator of cell--cell fusions. Interestingly, v- and t-SNAREs act similar to class I viral fusion proteins in that they form bundles of alpha-helices, which result in membrane apposition and fusion (Blumenthal et al. [@CR12]; Jahn et al. [@CR49]). Of the many proteins, which to date have been shown (or proposed) to be involved in cell fusions in mammals, only the syncytin family appears to use a similar alpha-helical mechanism. That they do is not surprising in view of the fact that syncytins represent conserved endogenous retroviral Env sequences. The founding family member, syncytin-1, was discovered as a protein capable of mediating fusions between cytotrophoblasts into syncytiotrophoblasts (Blond et al. [@CR11]; Mi et al. [@CR65]). This capability may have contributed to a high degree of evolutionary conservation of the syncytin-1 sequence. Syncytin-1 represents the Env protein of the human endogenous retroviral (HERV) W sequence, which entered the primate genome 25--40 million years ago. In contrast, most other retroviral sequences inserted in our genome have been subject to inactivating changes and probably represent garbage sequences. Molecular studies have shown that syncytin-1 (Env W) shares a structure similar to class I viral fusion proteins, especially in the region of the N- and C-terminal heptad repeats (NHR and CHR), and shares a common fusion mechanism with these proteins (Chang et al. [@CR19]; Gong et al. [@CR39]). A synthetic peptide derived from the CHR is also capable of inhibiting syncytin-1-mediated fusions by perturbing this mechanism (Chang et al. [@CR19]). Syncytin-1 binds to the D-type retroviral receptor ASCT-2 (Blond et al. [@CR11]) and may use another neutral amino acid transporter (ASCT-1) as an auxiliary receptor (Lavillette et al. [@CR60]). Syncytin antibodies, syncytin-1 downregulation through antisense oligonucleotides and the syncytin-1 CHR peptide have been shown to inhibit fusions between trophoblast-derived cells (Blond et al. [@CR11]; Chang et al. [@CR19]; Mi et al. [@CR65]). Agents increasing cellular levels of cAMP or cAMP analogues have been shown to promote cytotrophoblast fusions in vitro (Keryer et al. [@CR53]) and such agents are also known to elevate protein and mRNA levels of syncytin-1 in isolated cytotrophoblasts (Frendo et al. [@CR32]). Also estradiol may regulate syncytin-1 expression (Carino et al. [@CR15]) and the placenta-specific transcription factor GCMa interacts with two upstream sites in the HERV-W 5′-long terminal repeat and stimulates syncytin-1 transcription (Yu et al. [@CR95]). Additionally, experimentally induced truncations in the cytoplasmic tail of syncytin-1 increases its fusogenicity (Drewlo et al. [@CR26]), similar to what has been observed for some virally derived Env proteins (reviewed by Kubo et al. [@CR55]). However, if modifications in the cytoplasmic tail of syncytin-1 are of physiological importance for regulating fusogenicity has yet to be demonstrated.

A second syncytin-family member, syncytin-2, was subsequently found also to be expressed in the placenta (Blaise et al. [@CR10]). Syncytin-2 also represents a highly conserved endogenous retroviral envelope gene and is derived from the HERV FRD sequence (Blaise et al. [@CR10]). Immunocytochemical studies have localized syncytin-1 primarily to syncytiotrophoblasts as well as to cytotrophoblasts (Fig. [5](#Fig5){ref-type="fig"}). The exact localization is somewhat controversial (reviewed by Potgens et al. 2004), which may reflect differences in antibodies, fixation procedures and controls. A major point of concern is also the degree of cross-reactivity to the related sequences in syncytin-2, which recently was localized to a subpopulation of cytotrophoblasts (Malassiné et al. [@CR63]). The syncytin-1 receptor protein ASCT-2 was recently localized to cytotrophoblasts (Hayward et al. [@CR43]). More studies on the exact distribution of syncytin expression in the placenta using syncytin-1 and -2 specific antibodies seem warranted in order to exactly localize where fusions are likely to occur. Fig. 5Human term placenta immunocytochemically stained with a syncytin-1 peptide antiserum. Staining occurs in the syncytiotrophoblasts, which predominate at this stage. Nuclei are lightly counterstained with haematoxylin

Trophoblast cell fusions are, however, not unique to the primate placenta. Thus, also in the mouse placenta, trophoblasts fuse to form syncytiotrophoblasts but mice do, of course, not express HERV sequences. Amazingly, an in-silico search of the mouse genome unraveled the existence of two murine endogenous retroviral (MERV) Env genes, labeled syncytin-A and -B (Dupresssoir et al. [@CR29]). These genes were also fusogenic and orthologous genes were present in additional species of muridae (rats, gerbils, voles and hamsters) and appear to have entered the rodent lineage some 20 million years ago (Dupresssoir et al. [@CR29]). They were expressed in the placenta and at least syncytin-A has been shown to be involved in the formation of syncytiotrophoblasts in mice (Gong et al. [@CR38]). This represents an amazing example of parallel acquisition of retroviral genes of importance to reproduction in primates and rodents and poses the question whether also other species may have acquired similar viral genes of importance to cell fusions. The ability of syncytins to induce cell fusions may not be their only physiologic role. Thus, recent studies have shown that while syncytin-2 and syncytin-B also possess immunosuppressive activity, syncytin-1 and syncytin-A do not (Mangeney et al. [@CR64]). Syncytin-1 expression was originally detected in the placenta and testis (Blond et al. [@CR11]; Mi et al. [@CR65]) but subsequent studies have revealed the presence of syncytin-1 also in the brain (Antony et al. [@CR6]) and in breast, colon and endometrial cancers (Bjerregaard et al. [@CR9]; Strick et al. [@CR81], Larsen, Talts, Andersen, Bjerregaard and Larsson: work in progress). Syncytin-1 may also regulate production of inflammatory mediators (Antony et al. [@CR6]).

A number of additional molecules have been shown to be important to cell fusions. In fact, in all systems studied so far, from mating yeast to man, a bewildering array of mechanisms have been identified (see Chen and Olson [@CR21]; Chen et al. [@CR20]; Oren-Suissa and Podbilewicz [@CR70] for recent reviews). Molecules potentially involved in mammalian cell fusions include ADAM (a disintegrin and metalloproteinase domain) 12 (meltrin alpha), which has been associated with myoblast and osteoclast cell fusions (Abe et al. [@CR1]; Galliano et al. [@CR34]; Gilpin et al. [@CR35]; Yagami-Hiromasa et al. [@CR92]). In addition, ADAMs 1 and 2 (fertilins) may be involved in sperm--oocyte fusions, but do not seem indispensable for this function and, in man, the fertilin alpha gene is dysfunctional (Chen and Olson [@CR21]; Cho et al. [@CR22], [@CR23], Evans et al. [@CR30]; Jury et al. [@CR50], [@CR51]). In contrast, the tetraspanin protein CD9 is needed for sperm--oocyte fusions (Le Naour et al. [@CR61]). CD9 is also expressed by BeWo trophoblast tumor (choriocarcinoma) cells and has been linked both to BeWo invasiveness and to invasion during mouse embryo implantation (Hirano et al. [@CR46]; Liu et al. [@CR62]). CD9 has, together with another tetraspanin family member, CD81, also been linked to myoblast fusion and myotube maintenance (Tachibana and Hemler [@CR82]). Moreover, antibodies to either CD9 or CD81 have been shown to block fusions induced by Mason---Pfizer monkey virus---a D-type retrovirus (Duelli et al. [@CR27]). Tetraspanins are known to organize other proteins into membrane microdomains and may link to the actin cytoskeleton via EWI (Glu-Trp-Ile) and ERM (ezrin--radixin--moesin) proteins (Hemler [@CR44]; Sala-Valdés et al. [@CR78]). Possibly, their role as organizers of other proteins into microdomains may play a role in their involvement with cell fusions (Zivyat et al. [@CR96]). They do not express characteristics of fusogenic proteins like the syncytins, SNAREs and class I viral envelope proteins, but are coexpressed with syncytin-1, at least in BeWo cells. A macrophage fusion receptor (MFR, SIRPalpha), resembling CD4--the cell surface receptor for HIV---has been identified in macrophages (Saginario et al. [@CR76], [@CR77]; van den Berg et al. [@CR84]). MFR, which belongs to the immunoglobulin superfamily, binds another member of this family, CD47. CD47 is also structurally related to proteins expressed by Vaccinia and Variola viruses (Chen et al. [@CR20]). Whereas expression of MFR is restricted to myeloid cells and neurons, CD47 is ubiquitously expressed. MFR is transiently induced in macrophages at the onset of fusion while CD47 expression is constant. It has been hypothesized that CD47 initially binds to a long form of MFR to secure recognition and then switches to bind a shorter form to bring the plasma membranes closer (5--10 nm) for fusion (Vignery [@CR86]). Additionally, or alternatively, CD47 may promote calcium entry by forming a membrane pore (reviewed in Chen et al. [@CR20]). Also the hyaluronan receptor, CD44, is induced transiently when macrophages start to fuse. CD44 and MFR are subsequently cleaved by proteases during fusion. As mentioned above, CD9 and CD81 may also contribute to macrophage fusion. Additionally, DC-STAMP seems to be required for macrophage fusions. Mice lacking DC-STAMP are osteopetrotic and lack multinucleated osteoclasts and giant cells (Yagi et al. [@CR93]). DC-STAMP is a seven-transmembrane receptor, somewhat similar to the HIV co-receptor CXCR4, but a ligand has yet to be identified.

These and many more molecules, including integrins, vacuolar ATPase and receptors and their ligands, as well as different signaling intermediates have been associated with cell fusions. With the exception of the syncytins, most of the mammalian molecules so far studied do not fulfill strict criteria for fusogens and several are dispensable for fusions (reviewed by Chen and Olson [@CR21]; Chen et al. [@CR20]; Oren-Suissa and Podbilewicz [@CR70]). However, this may reflect molecular redundancy and does not definitely exclude that these molecules may participate in fusions. It is noteworthy that, in both man and mouse, two different syncytins are expressed and are both fusogenic. It is possible that, in the mammalian system, fusion requires a flotilla of molecules organized into membrane microdomains by proteins like CD9, encompassing receptors/ligands, signaling entities, proteases and fusogens of retroviral origin that are capable of forming alpha-helical bundles, which bring membranes closer. Syncytins and related retroviral envelope sequences may, in this connection, function both as fusogens and receptor ligands. However, it seems unlikely that as irreversible an event as a cell--cell fusion should depend upon a single receptor--ligand interaction. Thus, both facilitatory and inhibitory factors are expected to be part of the flotilla.

Cancer cell fusions {#Sec7}
-------------------

Studies by Mortensen et al. ([@CR68]) documented that human breast cancer cells fused with endothelial cells in culture. Stimulated by studies showing that syncytin-1 was involved in cytotrophoblast cell fusions (Blond et al. [@CR11]; Mi et al. [@CR65]), we examined whether a similar mechanism could account for cancer--endothelial cell fusions. Expression of syncytin-1 was documented in the breast cancer cell lines examined (MCF-7 and MDA-MB-231 cells; Bjerregaard et al. [@CR9], SK-BR-3 cells: Talts, Bjerregaard and Larsson: unpublished data). Moreover, we found that both tumor cells and endothelial cells expressed the syncytin-1 receptor ASCT-2. Use of phosphorthioate-protected syncytin-1 antisense oligonucleotides downmodulated syncytin-1 expression as measured by either quantitative RT-PCR or Western blotting and inhibited breast cancer--endothelial cell fusions, whereas a scrambled oligonucleotide control was without effect. Additionally, the syncytin-1 CHR peptide, referred to above, also inhibited the fusions whereas a control peptide was without effect (Bjerregaard et al. [@CR9]). However, neither the antisense nor the CHR peptide experiments effected a total inhibition of cancer-endothelial cell fusions. There may be several reasons to this. Thus, the antisense oligonucleotide did not totally downmodulate syncytin-1 levels and could therefore not be expected to decrease cell fusions to zero and the lack of total inhibition by the CHR peptide could potentially be ascribed to proteolytic degradation. However, we also detected that the breast cancer cells produced syncytin-2 and cannot exclude that also this molecule contributed to the cancer--host cell fusions. Further experiments using shRNA-directed downmodulation of both syncytin-1 and -2 as well as of additional putative fusogenic retroviral sequence are now underway to test this. Nevertheless, these data provide strong evidence that syncytin-1 is involved in mediating cancer--endothelial cell fusions in vitro.

We next examined two series of human breast cancer patients for tumoral expression of syncytin-1 using a polyclonal antiserum raised to a synthetic nonapeptide derived from the syncytin-1 sequence. In addition, tumors were also screened for expression of ASCT-2 using a peptide antiserum. Preabsorption of the antisera with the corresponding peptides, but not with irrelevant peptides, abolished staining (Larsson et al. [@CR59]) (Fig. [6](#Fig6){ref-type="fig"}). The results showed that 38% of all breast cancer samples showed detectable staining for syncytin and that endothelial cells expressed ASCT-2 (Fig. [6](#Fig6){ref-type="fig"}). Moreover, significant expression of ASCT-2 was detected also in many tumor cells (Fig. [6](#Fig6){ref-type="fig"}). The degree of syncytin immunostaining was visually graded using coded specimens and statistical analysis showed that it correlated positively with disease-free survival of the patients (Larsson et al. [@CR59]). Multivariate analysis included age dichotomized at 40 years, tumor size dichotomized at 20 mm, grade and adjuvant therapy and identified syncytin expression as an independent prognostic indicator of increased disease-free survival Also when used as a continuous variable, syncytin expression emerged as a significant prognostic indicator for disease-free survival in the Cox model (*P* = 0.02) (Larsson et al. [@CR59]). Fig. 6Human breast cancers immunocytochemically stained for syncytin-1 (**a**) or with antigen-preabsorbed antiserum (**b**) and for ASCT-2 (**c**, **e**) or with antigen-preabsorbed antiserum (**d**). Nuclei are lightly counterstained with haematoxylin. Note presence of syncytin immunoreactivity in tumor cells and of ASCT-2 immunoreactivity in endothelial cells (*arrows*) and in tumor cells

The involvement of syncytin-1 in tumor cell fusion events was subsequently confirmed by Strick et al. ([@CR81]), working with endometrial carcinomas. In their study, downmodulation of synctytin-1 expression also inhibited fusions between endometrial tumor cells. In agreement with findings on placental cells (vide supra), both cAMP elevating agents and estrogens upregulated syncytin-1 expression. However, only cAMP elevating agents stimulated cell fusions (Strick et al. [@CR81]). This apparent discrepancy may possibly be ascribed to the fact that estrogen treatment upregulated TGFbeta, which interfered with syncytin-induced fusions. Thus, estrogen did, in fact, stimulate cell fusions if TGFbeta was immunoneutralized. Conversely, additions of TGFbeta 1 or 3 reduced fusions induced by cAMP-elevating agents. This effect was observed both in endometrial carcinoma cells and in trophoblast-derived cells. These results show that both cAMP and estrogens positively may regulate syncytin-1 expression in tumor cells and that the TGFbeta family may negatively regulate the fusogenic effects of syncytin-1 in both trophoblasts and cancer cells (Strick et al. [@CR81]).

The role of syncytin-1 and cell fusions in cancer needs further study. Thus, our data show that syncytin-1 is not the only fusogenic protein expressed by breast cancer cells and the results presented by Strick et al. ([@CR81]) show that additional regulators, such as TGFbeta isoforms may be important modulators of cell fusions. So far, our breast cancer data indicate that syncytin-1 expression constitutes a positive prognostic factor. This is not the same as to say that cell fusions may be universally beneficial to cancers. First, syncytins may have additional effects within the tumor environment (Larsson et al. [@CR58], [@CR59]). Secondly, it seems likely that several factors within the cancer and its stroma (inactivated tumor suppressor genes, activated oncogenes, expression of fusogens and of CD9 and CD81 as well as TGFbeta) may act together to bring about a tumor profile that may be as diverse as the one demonstrated by the cell fusion experiments referred to above. Interestingly, however, expression of CD9 has been analyzed in a number of tumors and seems, like syncytin expression, to predict a good prognosis (Funakoshi et al. [@CR33]; Hashida et al. [@CR42]; Higashiyama et al. [@CR45]; Houle et al. [@CR48]; Miyake et al. [@CR66]; Uchida et al. [@CR83]). We propose that syncytins may be fusogens of importance to both trophoblast and cancer cell fusions and that they possibly also may mediate additional cell fusion events, acting in concert with other molecules with both enhancing and inhibitory regulatory effects.
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